Terazosin Capsule
Product Images NDC 71610-503

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71610-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 5 mg (71610 0503 60)

Label for Terazosin USP 5 mg capsules, containing 90 capsules. The label includes storage instructions to keep between 20-25 degrees Celsius, dispense in a tight light-resistant container, and to keep out of reach of children. The product is manufactured by Jubilant Cadista Pharmaceuticals Inc and repackaged by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also notes the product is Rx only.*

FDA Label Image

Bottle Label 2 mg (71610 0510 30)

Label for Terazosin capsules, 2 mg strength, from Aphena Pharma Solutions - Tennessee, LLC. The label includes the NDC 76160-0510-30, storage instructions to keep between 20-25°C (68-77°F), and directs dispensing in a light-resistant container as defined by USP. The label notes the drug is for oral use and lists the manufacturer as Jubilant Cadista Pharmaceuticals Inc. The package contains 30 capsules labeled for prescription use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride displayed as a 2D molecular diagram showing constituent atoms and bonds including aromatic rings, amine, and hydrochloride group.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

A two-part line graph showing mean changes over three months. The left graph depicts mean change in total symptom score from baseline comparing Terazosin and Placebo groups with sample sizes of 54 and 55 respectively. The right graph shows mean increase in peak flow rate (mL/sec) from baseline for Terazosin and Placebo groups, also with sample sizes of 54 and 52 respectively. Error bars indicate variability in measurements.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph showing the mean change from baseline over 30 months, with data points at months 0, 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30. The vertical axis represents 'Mean Change from Baseline' and ranges from 0 to -7. The graph includes two plotted lines, one with circles and one with no markers, depicting trends in mean change over time. Some data points are marked with asterisks indicating significance.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph showing the mean change from baseline over 30 months, with data points plotted monthly. The vertical axis represents the mean change, and the horizontal axis represents time in months. Asterisks indicate statistically significant changes at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.